320 related articles for article (PubMed ID: 32357546)
1. Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.
Chen YS; Hong ZX; Lin SZ; Harn HJ
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357546
[TBL] [Abstract][Full Text] [Related]
2. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
3. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Therapies for Machado-Joseph Disease.
Duarte-Silva S; Maciel P
Adv Exp Med Biol; 2018; 1049():369-394. PubMed ID: 29427114
[TBL] [Abstract][Full Text] [Related]
5. Towards the Identification of Molecular Biomarkers of Spinocerebellar Ataxia Type 3 (SCA3)/Machado-Joseph Disease (MJD).
Lima M; Raposo M
Adv Exp Med Biol; 2018; 1049():309-319. PubMed ID: 29427111
[TBL] [Abstract][Full Text] [Related]
6. Recent therapeutic prospects for Machado-Joseph disease.
Costa MDC
Curr Opin Neurol; 2020 Aug; 33(4):519-526. PubMed ID: 32657894
[TBL] [Abstract][Full Text] [Related]
7. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
8. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.
Matos CA; de Almeida LP; Nóbrega C
J Neurochem; 2019 Jan; 148(1):8-28. PubMed ID: 29959858
[TBL] [Abstract][Full Text] [Related]
9. Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial.
Saute JA; Rieder CR; Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; Souza DO; Saraiva-Pereira ML; Portela LV; Camey S; Torman VB; Jardim LB
J Neurol Sci; 2015 Nov; 358(1-2):72-6. PubMed ID: 26297649
[TBL] [Abstract][Full Text] [Related]
10. Spinocerebellar ataxia, type 3 (SCA3) is genetically identical to Machado-Joseph disease (MJD).
Haberhausen G; Damian MS; Leweke F; Müller U
J Neurol Sci; 1995 Sep; 132(1):71-5. PubMed ID: 8523034
[TBL] [Abstract][Full Text] [Related]
11. The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease.
Vasconcelos-Ferreira A; Carmo-Silva S; Codêsso JM; Silva P; Martinez ARM; França MC; Nóbrega C; Pereira de Almeida L
Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12763. PubMed ID: 34432315
[TBL] [Abstract][Full Text] [Related]
12. Neuromelanin imaging analyses of the substantia nigra in patients with Machado-Joseph disease.
Nakata Y; Sakamoto A; Kawata A
Neuroradiology; 2020 Nov; 62(11):1433-1439. PubMed ID: 32556403
[TBL] [Abstract][Full Text] [Related]
13. Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
de Assis AM; Saute JAM; Longoni A; Haas CB; Torrez VR; Brochier AW; Souza GN; Furtado GV; Gheno TC; Russo A; Monte TL; Castilhos RM; Schumacher-Schuh A; D'Avila R; Donis KC; de Mello Rieder CR; Souza DO; Camey S; Leotti VB; Jardim LB; Portela LV
Front Neurol; 2017; 8():485. PubMed ID: 28979235
[TBL] [Abstract][Full Text] [Related]
14. Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3.
Paulson HL
Semin Neurol; 2007 Apr; 27(2):133-42. PubMed ID: 17390258
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA profiling in the serums of SCA3/MJD patients.
Shi Y; Huang F; Tang B; Li J; Wang J; Shen L; Xia K; Jiang H
Int J Neurosci; 2014 Feb; 124(2):97-101. PubMed ID: 23879331
[TBL] [Abstract][Full Text] [Related]
16. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP; Herzog LK
Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
[TBL] [Abstract][Full Text] [Related]
17. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.
Nóbrega C; Mendonça L; Marcelo A; Lamazière A; Tomé S; Despres G; Matos CA; Mechmet F; Langui D; den Dunnen W; de Almeida LP; Cartier N; Alves S
Acta Neuropathol; 2019 Nov; 138(5):837-858. PubMed ID: 31197505
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3.
Siebert M; Donis KC; Socal M; Rieder CR; Emmel VE; Vairo F; Michelin-Tirelli K; França M; D'Abreu AC; Bettencourt C; Lima M; Lopes Cendes I; Saraiva-Pereira ML; Jardim LB
Parkinsonism Relat Disord; 2012 Feb; 18(2):185-90. PubMed ID: 22001711
[TBL] [Abstract][Full Text] [Related]
19. Cerebellar morphometric and spectroscopic biomarkers for Machado-Joseph Disease.
Miranda CO; Nobre RJ; Paiva VH; Duarte JV; Castelhano J; Petrella LI; Sereno J; Santana M; Afonso S; Januário C; Castelo-Branco M; de Almeida LP
Acta Neuropathol Commun; 2022 Mar; 10(1):37. PubMed ID: 35305685
[TBL] [Abstract][Full Text] [Related]
20. High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression.
Shi Y; Wang C; Huang F; Chen Z; Sun Z; Wang J; Tang B; Ashizawa T; Klockgether T; Jiang H
Cerebellum; 2015 Dec; 14(6):677-81. PubMed ID: 25869927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
